Filtered By:
Drug: Colcrys
Education: Study

This page shows you your search results in order of date.

Order by Relevance | Date

Total 60 results found since Jan 2013.

Insights into the Role of Inflammation in the Management of Atherosclerosis
J Inflamm Res. 2023 May 24;16:2223-2239. doi: 10.2147/JIR.S276982. eCollection 2023.ABSTRACTAtherosclerosis is the biological basis of ischemic heart disease and ischemic stroke, the leading causes of death in the world. After decades of studies, the understanding of atherosclerosis has evolved dramatically, and inflammation has been recognized as one of the most relevant pillars in all phases of atherosclerotic disease. Nevertheless, only recently, the trial CANTOS, and subsequent outcome studies with colchicine, finally provided proof-of-concept evidence that anti-inflammatory therapies were able to reduce cardiovascular...
Source: Atherosclerosis - May 30, 2023 Category: Cardiology Authors: Viviane Zorzanelli Rocha Fabiana Hanna Rached Marcio Hiroshi Miname Source Type: research

Lipoprotein (a), Inflammation, and Atherosclerosis
J Clin Med. 2023 Mar 27;12(7):2529. doi: 10.3390/jcm12072529.ABSTRACTGrowing evidence has shown that high levels of lipoprotein (a) (Lp(a)) and chronic inflammation may be responsible for the residual risk of cardiovascular events in patients managed with an optimal evidence-based approach. Clinical studies have demonstrated a correlation between higher Lp(a) levels and several atherosclerotic diseases including ischemic heart disease, stroke, and degenerative calcific aortic stenosis. The threshold value of Lp(a) serum concentrations associated with a significantly increased cardiovascular risk is >125 nmol/L (50 mg/dL...
Source: Atherosclerosis - April 13, 2023 Category: Cardiology Authors: Stefania Angela Di Fusco Aldo Pietro Maggioni Pietro Scicchitano Marco Zuin Emilia D'Elia Furio Colivicchi Source Type: research

Inflammation May Be the Culprit Behind Our Deadliest Diseases
In the early days of my medical residency, I met a man whom we’ll call Jason. He arrived to our emergency room on a holiday, nonchalant yet amiable, and complained of mild chest pain. Jason was tall and trim, with a strong South Boston accent and fingertips still faintly stained from his last home-improvement project. He was only 45 years old, but he looked much younger. He didn’t smoke, barely drank alcohol, and his cholesterol levels had always been normal. No one in his family had a history of heart disease. He asked us if we could work quickly—he wanted to be home for dinner with his daughters. [time-...
Source: TIME: Health - April 11, 2023 Category: Consumer Health News Authors: Shilpa Ravella Tags: Uncategorized freelance health Source Type: news

Colchicine in Athero-Thrombosis: Molecular Mechanisms and Clinical Evidence
Int J Mol Sci. 2023 Jan 27;24(3):2483. doi: 10.3390/ijms24032483.ABSTRACTSeveral lines of evidence have clearly indicated that inflammation plays a pivotal role in the development of atherosclerosis and of its thrombotic complications such as acute coronary syndromes or ischemic stroke. Thus, it has been postulated that the use of anti-inflammatory agents might be extremely useful to improve cardiovascular outcome. Recently, increasing attention has been reserved to one of the oldest plant-derived drugs still in use in clinical practice, colchicine that has been used as drug to treat inflammatory diseases such gout or Medi...
Source: Atherosclerosis - February 11, 2023 Category: Cardiology Authors: Giovanni Cimmino Francesco S Loffredo Gennaro De Rosa Plinio Cirillo Source Type: research

Colchicine in the Management of Acute Coronary Syndrome: A Meta-analysis
ConclusionsThese data suggest colchicine, in addition to guideline-directed medical therapy following acute coronary syndrome reduces MACE, cerebrovascular accidents, and rates of urgent revascularization at 2 years of follow-up.
Source: Cardiology and Therapy - January 6, 2023 Category: Cardiology Source Type: research

Pharmacotherapy for stroke prevention in nonvalvular atrial fibrillation: current strategies and future directions
This article reviews current pharmacotherapeutic options for prevention of stroke in NVAF, paying special attention to their use in particular clinical settings (e.g.: cardioversion, catheter ablation). We also aim to review new drug candidates that have entered clinical studies in this indication.EXPERT OPINION: Oral anticoagulant therapy (OAT) remains the mainstay for ischemic stroke prophylaxis in NVAF in patients at risk. Several oral (asundexian, milvexian) and parenteral (abelacimab, osocimab, xisomab, IONIS-FXIRX, fesomersen) factor XIa inhibitors are under development. These new compounds appear to be associated wi...
Source: Expert Opinion on Pharmacotherapy - November 18, 2022 Category: Drugs & Pharmacology Authors: Antonio G ómez-Outes M Luisa Su árez-Gea Alejandro-Isidoro P érez-Cabeza Jose Manuel Garc ía-Pinilla Source Type: research

Evaluating the Utility of Colchicine in Acute Coronary Syndrome: A Systematic Review and Meta-Analysis
Abstract: Colchicine has demonstrated promising effects in inhibiting local and systemic inflammation during acute coronary syndrome (ACS). However, the efficacy of colchicine in ACS is controversial. We performed a meta-analysis to assess the utility of colchicine in ACS by systematically searching randomized controlled trials. Recurrent myocardial infarction, coronary revascularization, and stroke were included as efficacy endpoint parameters whereas safety endpoints chosen were all-cause mortality, cardiovascular mortality, infectious events, and gastrointestinal (GI) adverse events. Nine identified studies were inc...
Source: Journal of Cardiovascular Pharmacology - November 1, 2022 Category: Cardiology Tags: Review Article Source Type: research

Colchicine and the combination of rivaroxaban and aspirin in patients hospitalised with COVID-19 (ACT): an open-label, factorial, randomised, controlled trial
Lancet Respir Med. 2022 Oct 10:S2213-2600(22)00298-3. doi: 10.1016/S2213-2600(22)00298-3. Online ahead of print.ABSTRACTBACKGROUND: COVID-19 disease is accompanied by a dysregulated immune response and hypercoagulability. The Anti-Coronavirus Therapies (ACT) inpatient trial aimed to evaluate anti-inflammatory therapy with colchicine and antithrombotic therapy with the combination of rivaroxaban and aspirin for prevention of disease progression in patients hospitalised with COVID-19.METHODS: The ACT inpatient, open-label, 2 × 2 factorial, randomised, controlled trial was done at 62 clinical centres in 11 countries. Patient...
Source: Respiratory Care - October 13, 2022 Category: Respiratory Medicine Authors: John W Eikelboom Sanjit S Jolly Emilie P Belley-Cote Richard P Whitlock Sumathy Rangarajan Lizhen Xu Laura Heenan Shrikant I Bangdiwala Maria Luz Diaz Rafael Diaz Afzalhussein Yusufali Sanjib Kumar Sharma Wadea M Tarhuni Mohamed Hassany Alvaro Avezum Will Source Type: research

Effect of different doses of colchicine on high sensitivity C-reactive protein in patients with acute minor stroke or transient ischemic attack: A pilot randomized controlled trial
CONCLUSION: Early treatment with low dose of colchicine reduced hsCRP levels in the patients with acute minor ischemic stroke and TIA.PMID:36041708 | DOI:10.1016/j.ejps.2022.106288
Source: European Journal of Pharmaceutical Sciences - August 30, 2022 Category: Drugs & Pharmacology Authors: Baoshi Yuan Xia Meng Anxin Wang Siying Niu Xuewei Xie Jing Jing Hao Li Liguo Chang Yongjun Wang Jiejie Li Source Type: research